MedTrace Logo

CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation

NCT07672964 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant. It will also learn about the safety of this treatment. The main questions it aims to answer are:

Does this treatment lower the chance of getting serious viral infections after transplant? What medical problems do patients have when receiving this treatment?

Conditions

  • Hematologic Malignancy
  • Haplo-identical HCT

Interventions

BIOLOGICAL

CD45RA-depleted DLI

CD45RA Depleted DLI by ex vivo CliniMACS® prepared from mononuclear cell leukapheresis

Sponsors & Collaborators

  • Shanghai Liquan Hospital

    collaborator OTHER

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-07-31
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07672964 on ClinicalTrials.gov